News MSD, AZ partner LaNova bought by Sino Biopharm for $951m LaNova Medicines is being bought out by minority shareholder Sino Biopharm in a deal valued at around $951 million.
News AbbVie cuts $1.9bn+ deal with IGI for trispecific antibody AbbVie has signed another deal in its effort to build an industry-leading position in multispecific antibodies for blood cancers.
Oncology On nuclear medicine and oncology, SHINE Technologies Greg Piefer, founder and CEO of SHINE Technologies, discusses nuclear medicine and the role of radiopharmaceuticals in oncology.
News NICE backs new drugs for Crohn's disease, lymphoma Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.
News Concentra throws lifeline to troubled CARGO Therapeutics After cutting staff and halting development of its CAR-T therapies, CARGO has agreed to a takeover by Kevin Tang's Concentra Bio.
News New radiopharma Actithera emerges with $75.5m in financing A new player in radioligand therapies, Actithera, has arrived on the scene with $75.5m in funding and lead FAP-targeted candidate for cancer.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
